Trial Information
Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy. A Prospective Placebo Double Blind Study
Inclusion Criteria:
- Invasive breast cancer post-menopausal women
- Estrogen and/or progesterone receptor positive
Exclusion Criteria:
- Patients with endocrine disease
- Hormone therapy users or those who had been pregnant in the last 12 months before the
diagnosis
- Patients with a negative expression for estrogen and/or progesterone receptors
- Women with a history of thromboembolism
- Patients who had previously undergone any treatment for breast cancer
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Basic Science
Outcome Measure:
Expression of progesterone
Outcome Time Frame:
end of the study (june 2008)
Safety Issue:
No
Principal Investigator
Andre Mattar, MD
Investigator Role:
Principal Investigator
Authority:
Brazil: Ethics Committee
Study ID:
0904/04
NCT ID:
NCT01016665
Start Date:
April 2005
Completion Date:
June 2008
Related Keywords:
- Breast Cancer
- Breast cancer
- Short Term
- Homontherapy
- aromatase inhibitor
- Short term hormonetherapy in breast cancer
- Breast Neoplasms